Human drosomycin-like defensin
Need Assistance?
  • US & Canada:
    +
  • UK: +

Human drosomycin-like defensin

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Human drosomycin-like defensin is an antibacterial peptide isolated from Homo sapiens. It has activity against fungi.

Category
Functional Peptides
Catalog number
BAT-012421
Synonyms
Cys-Leu-Ala-Gly-Arg-Leu-Asp-Lys-Gln-Cys-Thr-Cys-Arg-Arg-Ser-Gln-Pro-Ser-Arg-Arg-Ser-Gly-His-Glu-Val-Gly-Arg-Pro-Ser-Pro-His-Cys-Gly-Pro-Ser-Arg-Gln-Cys-Gly-Cys-His-Met-Asp
Sequence
CLAGRLDKQCTCRRSQPSRRSGHEVGRPSPHCGPSRQCGCHMD
1. Drosomycin-like defensin, a human homologue of Drosophila melanogaster drosomycin with antifungal activity
Anna Simon, et al. Antimicrob Agents Chemother. 2008 Apr;52(4):1407-12. doi: 10.1128/AAC.00155-07. Epub 2008 Jan 22.
Innate antifungal defense in Drosophila melanogaster relies on the activation of the Toll molecule and the release of drosomycin, a defensin-like molecule with antifungal properties. Ten human homologues of Toll have been described, with central roles in activation of the innate host defense. In the present study, we report a putative human homologue of the Drosophila-derived drosomycin, designated drosomycin-like defensin (DLD). Synthetic DLD displays a broad spectrum of activity against Aspergillus spp. and other clinically relevant filamentous fungi. These effects are specific for filamentous fungi; no activity has been found against yeasts or gram-positive or gram-negative bacteria. Synthetic DLD also displays immunomodulatory effects on Aspergillus-stimulated cytokine production. In addition, we show the expression of DLD mRNA in several human tissues, particularly in the skin, consistent with its putative role as a defensin against invading microorganisms. This is the first indication of an endogenous human peptide with specific antifungal activity, which is probably central in the defense against infections with molds.
2. Expression profile of drosomycin-like defensin in oral epithelium and oral carcinoma cell lines
Jun Sato, Michiko Nishimura, Mami Yamazaki, Kouki Yoshida, Yoshihito Kurashige, Masato Saitoh, Yoshihiro Abiko Arch Oral Biol. 2013 Mar;58(3):279-85. doi: 10.1016/j.archoralbio.2012.09.006. Epub 2012 Oct 22.
Objective: Drosomycin-like defensin (DLD) is a recently discovered antimicrobial peptide mainly active against filamentous fungi. The present study investigated the expression profile of DLD in oral epithelium and oral squamous cell carcinoma (SCC) cell lines. Methods: Tissue sections of human oral mucosa, keratinocytes derived from oral mucosa (NOK) and eight kinds of SCC cell lines were used. In situ hybridization was performed on tissue sections of oral mucosa. Expression levels of DLD in the cells were observed by reverse transcription polymerase chain reaction (RT-PCR) and real-time RT-PCR assays. The cells were treated with IL-1β, IL-8 and TNF-α, and agonists for TLR2, TLR4 and β-glucan. DLD expression in cells was increased and decreased by the DLD gene and its siRNA transfection, respectively. The proliferation rates were assessed by cell counting. Results: By means of in situ hybridization, DLD mRNA positive staining was detected in the epithelial layer of the oral mucosa. An RT-PCR assay confirmed the expression of DLD mRNA in keratinocytes derived from oral epithelium. Expression of DLD in two out of eight cell lines was significantly lower than in NOK cells. The expression levels of DLD mRNA were not significantly changed in the cells stimulated with any cytokines or agonists. The cell proliferation rate where there was decreased expression of DLD was significantly lower than in the control. Conclusion: DLD may be partially involved in the defence against filamentous fungal infection in the oral mucosa, and may also serve other functions, such as contribution to cell growth.
Online Inquiry
Verification code
Inquiry Basket